GlobeNewswire Inc.··NaApogee Therapeutics to Unveil 52-Week Phase 2 Data for APG777 Atopic Dermatitis Treatment
Apogee Therapeutics to present 52-week Phase 2 data for APG777 in atopic dermatitis on March 23, 2026, signaling major clinical development milestone.
APGEbiologicsatopic dermatitis